PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking. / Massarenti, Laura; Enevold, Christian; Damgaard, Dres; Ødum, Niels; Garred, Peter; Frisch, Morten; Shelef, Miriam A.; Jacobsen, Søren; Nielsen, Claus Henrik.

In: Frontiers in Immunology, Vol. 12, 707690, 2021.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Massarenti, L, Enevold, C, Damgaard, D, Ødum, N, Garred, P, Frisch, M, Shelef, MA, Jacobsen, S & Nielsen, CH 2021, 'PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking', Frontiers in Immunology, vol. 12, 707690. https://doi.org/10.3389/fimmu.2021.707690

APA

Massarenti, L., Enevold, C., Damgaard, D., Ødum, N., Garred, P., Frisch, M., Shelef, M. A., Jacobsen, S., & Nielsen, C. H. (2021). PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking. Frontiers in Immunology, 12, [707690]. https://doi.org/10.3389/fimmu.2021.707690

Vancouver

Massarenti L, Enevold C, Damgaard D, Ødum N, Garred P, Frisch M et al. PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking. Frontiers in Immunology. 2021;12. 707690. https://doi.org/10.3389/fimmu.2021.707690

Author

Massarenti, Laura ; Enevold, Christian ; Damgaard, Dres ; Ødum, Niels ; Garred, Peter ; Frisch, Morten ; Shelef, Miriam A. ; Jacobsen, Søren ; Nielsen, Claus Henrik. / PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking. In: Frontiers in Immunology. 2021 ; Vol. 12.

Bibtex

@article{db9573e3f8204b58b86fa8c5626e3c99,
title = "PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking",
abstract = "Peptidylarginine deiminases (PADs) catalyze citrullination, a post-translational modification playing a pathogenic role in anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA). The interplay between single nucleotide polymorphisms (SNPs) in the PADI genes and known risk factors for ACPA-positive RA, including smoking, HLA-DR4 and -1, and the PTPN22 R620W polymorphism, was investigated. We typed four PADI2 SNPs, four PADI4 SNPs, and the PTPN22 R620W SNP in 445 Danish RA patients and 533 age-matched healthy controls, as well as in 200 North American RA patients and 100 age- and sex-matched controls. The HLA-DRB1 locus was typed in the Danish cohort. Logistic regression analyses, adjusted for age, sex, smoking status, and PTPN22 R620W, revealed increased risk of anti-CCP-positive RA in carriers of rs11203367(T) (OR: 1.22, p=0.03) and reduced risk in carriers of rs2240335(A) in PADI4 (OR: 0.82, p=0.04). rs74058715(T) in PADI4 conferred reduced risk of anti-CCP-negative RA (OR: 0.38, p=0.003). In HLA-DRB1*04-positive individuals, specifically, the risk of anti-CCP-positive RA was increased by carriage of PADI4 rs1748033(T) (OR: 1.54, p=0.007) and decreased by carriage of PADI4 rs74058715(T) (OR: 0.44, p=0.01), and we observed an interaction between these SNPs and HLA-DRB1*04 (p=0.004 and p=0.008, respectively) Thus, PADI4 polymorphisms associate with ACPA-positive RA, particularly in HLA-DRB1*04-positive individuals, and with ACPA-negative RA independently of HLA-DRB1*04.",
keywords = "anti-citrullinated proteins antibodies (ACPA), HLA-DRB1*04, peptidylarginine deiminase (PAD), rheumatoid arthritis, single nucleotide polymorphism (SNP)",
author = "Laura Massarenti and Christian Enevold and Dres Damgaard and Niels {\O}dum and Peter Garred and Morten Frisch and Shelef, {Miriam A.} and S{\o}ren Jacobsen and Nielsen, {Claus Henrik}",
note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Massarenti, Enevold, Damgaard, {\O}dum, Garred, Frisch, Shelef, Jacobsen and Nielsen.",
year = "2021",
doi = "10.3389/fimmu.2021.707690",
language = "English",
volume = "12",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking

AU - Massarenti, Laura

AU - Enevold, Christian

AU - Damgaard, Dres

AU - Ødum, Niels

AU - Garred, Peter

AU - Frisch, Morten

AU - Shelef, Miriam A.

AU - Jacobsen, Søren

AU - Nielsen, Claus Henrik

N1 - Publisher Copyright: © Copyright © 2021 Massarenti, Enevold, Damgaard, Ødum, Garred, Frisch, Shelef, Jacobsen and Nielsen.

PY - 2021

Y1 - 2021

N2 - Peptidylarginine deiminases (PADs) catalyze citrullination, a post-translational modification playing a pathogenic role in anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA). The interplay between single nucleotide polymorphisms (SNPs) in the PADI genes and known risk factors for ACPA-positive RA, including smoking, HLA-DR4 and -1, and the PTPN22 R620W polymorphism, was investigated. We typed four PADI2 SNPs, four PADI4 SNPs, and the PTPN22 R620W SNP in 445 Danish RA patients and 533 age-matched healthy controls, as well as in 200 North American RA patients and 100 age- and sex-matched controls. The HLA-DRB1 locus was typed in the Danish cohort. Logistic regression analyses, adjusted for age, sex, smoking status, and PTPN22 R620W, revealed increased risk of anti-CCP-positive RA in carriers of rs11203367(T) (OR: 1.22, p=0.03) and reduced risk in carriers of rs2240335(A) in PADI4 (OR: 0.82, p=0.04). rs74058715(T) in PADI4 conferred reduced risk of anti-CCP-negative RA (OR: 0.38, p=0.003). In HLA-DRB1*04-positive individuals, specifically, the risk of anti-CCP-positive RA was increased by carriage of PADI4 rs1748033(T) (OR: 1.54, p=0.007) and decreased by carriage of PADI4 rs74058715(T) (OR: 0.44, p=0.01), and we observed an interaction between these SNPs and HLA-DRB1*04 (p=0.004 and p=0.008, respectively) Thus, PADI4 polymorphisms associate with ACPA-positive RA, particularly in HLA-DRB1*04-positive individuals, and with ACPA-negative RA independently of HLA-DRB1*04.

AB - Peptidylarginine deiminases (PADs) catalyze citrullination, a post-translational modification playing a pathogenic role in anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA). The interplay between single nucleotide polymorphisms (SNPs) in the PADI genes and known risk factors for ACPA-positive RA, including smoking, HLA-DR4 and -1, and the PTPN22 R620W polymorphism, was investigated. We typed four PADI2 SNPs, four PADI4 SNPs, and the PTPN22 R620W SNP in 445 Danish RA patients and 533 age-matched healthy controls, as well as in 200 North American RA patients and 100 age- and sex-matched controls. The HLA-DRB1 locus was typed in the Danish cohort. Logistic regression analyses, adjusted for age, sex, smoking status, and PTPN22 R620W, revealed increased risk of anti-CCP-positive RA in carriers of rs11203367(T) (OR: 1.22, p=0.03) and reduced risk in carriers of rs2240335(A) in PADI4 (OR: 0.82, p=0.04). rs74058715(T) in PADI4 conferred reduced risk of anti-CCP-negative RA (OR: 0.38, p=0.003). In HLA-DRB1*04-positive individuals, specifically, the risk of anti-CCP-positive RA was increased by carriage of PADI4 rs1748033(T) (OR: 1.54, p=0.007) and decreased by carriage of PADI4 rs74058715(T) (OR: 0.44, p=0.01), and we observed an interaction between these SNPs and HLA-DRB1*04 (p=0.004 and p=0.008, respectively) Thus, PADI4 polymorphisms associate with ACPA-positive RA, particularly in HLA-DRB1*04-positive individuals, and with ACPA-negative RA independently of HLA-DRB1*04.

KW - anti-citrullinated proteins antibodies (ACPA)

KW - HLA-DRB104

KW - peptidylarginine deiminase (PAD)

KW - rheumatoid arthritis

KW - single nucleotide polymorphism (SNP)

U2 - 10.3389/fimmu.2021.707690

DO - 10.3389/fimmu.2021.707690

M3 - Journal article

C2 - 34733271

AN - SCOPUS:85118322187

VL - 12

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 707690

ER -

ID: 284700571